Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

EarningsWegovy®Positive

AI Analysis

Summary

Novo Nordisk reported Q1 2026 adjusted operating profit of DKK 32,858 million, with strong Wegovy performance driving a raise to 2026 guidance for adjusted sales.

Financial Highlights

Guidance

raised for 2026

Importance:6/10

Sentiment:

0.70

Q1 2026 earningsguidance raiseWegovy growthInternational Operations

Related Companies

$NVO

Read the original article

Published by GlobeNewswire Pharma on May 6, 2026 5:31 AM

Read Original